A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Mucosal Melanoma Clinical Trial

Official title:

A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02978443
• Other study ID #: 2016-0420
• Secondary ID: CA209-763
• Status: Terminated
• Phase: Phase 2
• Start date: July 26, 2017
• Est. completion date: August 2, 2022

Study information

• Verified date: March 2024
• Source: Georgetown University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Participants with advanced or metastatic mucosal melanoma (cohort A) and acral lentiginous melanoma (cohort B) eligible for treatment with nivolumab in combination with ipilimumab followed by nivolumab therapy will submit tissue blocks from tumors of malignant melanoma for histopathology review and immunohistochemistry analysis at Georgetown University-Lombardi Comprehensive Cancer Center. Pretreatment blood will be drawn and stored in the Melanoma Research Foundation Breakthrough Consortium Virtual Repository at each participating institution. At the end of participation, samples will be sent to Georgetown University-Lombardi Comprehensive Cancer Center for processing and storage. An optional pretreatment biopsy of an accessible tumor lesion will be performed in a subset of enrolled patients. Patients will receive nivolumab in combination with ipilimumab according to the standard FDA approved treatment regimen.

Description:

Immunotherapy with HD-IL-2 has produced durable benefit in 10% of patients with metastatic cutaneous melanoma. The antitumor activity of IL-2 has been limited at least in part by immunosuppressive and immune-regulatory forces within the tumor microenvironment. Antibodies against CTLA4 (e.g. ipilimumab), PD1 and its ligand (PD-L1) produced long-term benefit in approximately 20-40% of patients with advanced melanoma. In addition, the combination of ipilimumab with the anti-PD1 antibody, nivolumab, has shown tumor responses in up to 60% of patients with advanced melanoma. These findings have led to FDA approval of ipilimumab and nivolumab as an indication for treatment of patients with advanced melanoma and nivolumab for other cancers. While these data are exciting, only a few patients enrolled to the prior studies had metastatic MCM or ALM. There is no prospective immunotherapy studies conducted in MCM or ALM-specific population. Therefore the activity of the ipilimumab + nivolumab combination in these subsets or patients remains unknown

Reliable predictive biomarkers for the use of immune checkpoint inhibitors are needed to identify pretreatment those patients most likely to respond and early on in treatment assays could help identify mechanisms of tumor response and resistance necessary to improve therapy. Although tumor PD-L1 expression in tumor confers higher treatment response rate, responses to nivolumab or nivolumab + ipilimumab alone were noted in 55% and 41% of patients, respectively, with PD-L1- tumors. Therefore, more reliable predictive biomarkers are needed.

Recently, extensive studies on metastatic colorectal cancer have demonstrated that a new scoring system as well as density of immune cells infiltrates at the center of the tumor and its invasive margin, described as Immunoscore, could accurately separate a group of patients with high Immunoscore with improved DFS, and OS from those with low Immunoscore where the histopathological staging system cannot. A recent study has also demonstrated relationship between degree of pre-treatment CD8+ tumor infiltrating lymphocytes (TILs) infiltration and PD-L1 expression at the invasive margin of the advanced cutaneous melanoma and improved long-term clinical benefits in patients with advanced melanoma who received pembrolizumab monotherapy. Further, there appeared to be an association between tumor response and clonality of the immune infiltrate based on a next-generation sequencing method used to evaluate T-cell receptor rearrangement pre- and in response to checkpoint inhibitor therapy. Also, high mutational burden correlated with overall survival in patients with cutaneous melanoma treated with ipilimumab or lung cancer treated with anti-PD1. However, the biology of MCM and ALM are distinct from cutaneous melanoma at multiple levels. Consequently, the utility of predictive biomarkers developed for cutaneous melanoma remains unknown.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: August 2, 2022
• Est. primary completion date: July 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically confirmed MCM or ALM that is metastatic or unresectable.

• Patients must be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelines.

• Patients must have a tissue block (or 20 unstained slides) available with adequate tumor to perform multiplex immunohistochemistry and nucleic acids analyses ( i.e. whole exome sequencing) Patients with only a previous fine-needle aspirate are ineligible for enrollment.

• Patients must be willing to donate a small amount of whole blood prior to treatment and during treatment for laboratory analysis.

• Patients must give informed consent prior to initiation of therapy.

• Patients must be ambulatory with good performance status (ECOG 0 or 1)

Exclusion Criteria:

• Patients who do not have available tissue for immunohistochemistry and nucleic acids analyses.

• Patients who have received prior immunotherapy for unresectable or metastatic disease.

• Patients with untreated brain metastases, leptomeningeal disease, or seizure disorders are ineligible. Patients with a history of brain metastases must have completed treatment (i.e. surgery or radiation) 1 month prior to enrollment and have no evidence of disease or edema on brain CT or head MRI.

• Patients with inadequate tissue for analysis.

Related Conditions & MeSH terms

• Acral Lentiginous Melanoma
• Melanoma
• Mucosal Melanoma

Intervention

Drug:
• Nivolumab
nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
• Ipilimumab
ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)

Locations

Country	Name	City	State
United States	John Theurer Cacner Center at Hackensack University Medical Center	Hackensack	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	H. Lee Moffitt Cancer Center and Research Institute	Tampa	Florida
United States	Lombardi Comprehensive Cancer Center	Washington	District of Columbia
United States	Washington Cancer Institute at MedStar Washington Hospital Center	Washington	District of Columbia

Sponsors (14)

Lead Sponsor

Collaborator

Georgetown University

Bristol-Myers Squibb, Columbia University, Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, M.D. Anderson Cancer Center, Melanoma Research Foundation Breakthrough Consortium, Memorial Sloan Kettering Cancer Center, Northwestern University, University of California, San Francisco, University of Colorado, Denver, University of Pittsburgh, Vanderbilt University, Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR) With Mucosal Melanoma (MCM)	ORR, defined as complete response [CR] + partial response [PR] per RECIST 1.1 criteria and to compare this response rate to the response rate of patients with "good" molecular predictive features	24 months
Secondary	Objective Response Rate With Acral Lentiginous Melanoma (ALM)	ORR, defined as complete response [CR] + partial response [PR] per RECIST 1.1 criteria and to compare this response rate to the response rate of patients with "good" molecular predictive features	24 months
Secondary	Progression-free Survival (PFS)	Progression-free survival is defined as the time from the date of treatment initiation until the date that disease progression criteria are met or the date death without progression, or is censored at the date of last disease assessment without evidence of progression.	33 months
Secondary	Overall Survival (OS)	OS is calculated from the date of treatment initiation to the date of death, or censored at date of last contact.	44 months